IP Library Granted Patent US 8,728,026
Granted Patent B2
US 8,728,026 · App. 11/295,677 · Granted May 20, 2014

Devices and methods for treating aortic valve stenosis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,728,026
App. No.
11/295,677
Granted
May 20, 2014
Kind
B2
Abstract

Devices and methods for their use in increasing the aortic valve flow of a stenotic aortic valve are provided. The subject devices include an aortic valve isolation element and an aortic valve flushing element. The aortic valve isolation element is made up of a ventricular side aortic valve occlusion element, coronary ostia occlusion elements and an ascending aorta occlusion element. The aortic valve flushing element is made up of a dissolution fluid introducing element and a fluid removal element. In practicing the subject methods, a stenotic aortic valve is first isolated. Next, the isolated valve is flushed with a dissolution fluid, e.g., an acidic dissolution fluid, for a period of time sufficient for the aortic valve flow of the treated valve to be increased. In certain embodiments, the valve is also contacted with a dissolution fluid attenuating fluid, e.g., a buffer, during the flushing step in order to limit the contact of non-valve tissue with the dissolution fluid. Also provided are systems and kits that include the subject devices and can be employed in practicing the subject methods. The subject devices, methods, systems and kits find use in treating conditions associated with the presence of stenotic aortic valves.

Claims (8)

1. A device for treating aortic valve stenosis utilizing a dissolution fluid, the device comprising:

a fluid aspiration element having a substantially tubular shape;

an ascending aortic occlusion element positioned around an outer surface of the fluid aspiration element and sized to occlude the ascending aorta;

a first fluid delivery element having a substantially tubular configuration and arranged slidably and concentrically within the fluid aspiration element creating a first annular gap therebetween;

a second fluid delivery element having a substantially tubular configuration and arranged slidably and concentrically within the first fluid delivery element creating a second annular gap therebetween;

coronary ostia occlusion elements positioned in the second annular gap between the first and second fluid delivery elements, each element having a balloon dimensioned for insertion into the entrance of the left and right coronary arteries and a guidewire lumen;

a ventricular side aortic valve occlusion element positioned slidably and concentrically within the second fluid delivery element, the ventricular side aortic valve occlusion element having a balloon dimensioned to occlude the ventricular side of the aortic valve and a guidewire lumen; and

a guidewire disposed within the guidewire lumen of the ventricular side aortic valve occlusion element.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2025
From: CARDINAL HEALTH SWITZERLAND 515 GMBH; CARDINAL HEALTH 529, LLC; CORDIS CORPORATION; FLEXIBLE STENTING SOLUTIONS, INC
To: CORDIS US CORP
Reel/Frame 072987/0675 →
SECURITY INTEREST Recorded Oct 1, 2025
From: CORDIS US CORP.; ACCESS CLOSURE, LLC
To: HPS INVESTMENT PARTNERS, LLC
Reel/Frame 072973/0157 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2017
From: CORDIS CORPORATION
To: CARDINAL HEALTH SWITZERLAND 515 GMBH
Reel/Frame 042126/0259 →